(Photo Courtesy: www.thesun.co.uk)
The Methicillin-Resistant Staphylococcus Aureus (MRSA) treatment market will experience very limited growth over the next decade, rising from $1.4 billion in 2014 to $1.45 billion by 2024, according to research and consulting firm GlobalData.
The company's latest report states that the $50 million increase, which will occur across the seven major markets (7MM) of the US, Japan, the UK, France, Italy, Spain, and Germany, represents a very modest Compound Annual Growth Rate (CAGR) of 0.4%.
This minimal increase will be largely the product of a treatment space dominated by three primary agents, namely vancomycin, Zyvox (linezolid), and Cubicin (daptomycin).
However, Dr Christopher J Pace, GlobalData's Director of Infectious Diseases, emphasizes that opportunities within the market are rife, even with its ostensible homogeneity.
Dr Pace says: "Despite its status as the most commonly prescribed antibiotic for MRSA infections, vancomycin has a substantial number of clinical drawbacks.